IKONISYS: management transactions · France · AMF

About IKONISYS

IKONISYS is a medtech company focused on automated cell-based diagnostics, with a strong specialization in oncology and rare-cell detection. Founded in New Haven, Connecticut, the group built its reputation around the proprietary Ikoniscope® digital microscope, a fully automated platform designed to detect, analyze and enumerate rare cells with high precision. Its core offering combines hardware, software and reagents, leveraging FISH (Fluorescence In Situ Hybridization) technology alongside cytology-oriented diagnostic workflows. From a corporate history perspective, Ikonisys initially developed as a technology-driven diagnostics company focused on automating medical imaging and laboratory interpretation. A key milestone was its admission to trading on Euronext Growth Paris in 2021, which helped finance the expansion of the Ikoniscope platform in Europe and the United States. The company subsequently broadened its industrial scope through the acquisition of Hospitex International, strengthening its exposure to cytology and oncology diagnostics. By 2025-2026, the group has also been communicating under the Aliko Scientific identity, while continuing to use the Ikonisys brand for its technology and commercial solutions. Its business model is centered on the sale of automated instruments, FISH diagnostic applications and related consumables, as well as liquid-based cytology and laboratory workflow automation solutions. The company highlights clinical applications across several cancer types, including bladder, breast, cervical, prostate and lung cancers, together with selected hematology applications. The value proposition is built on improving standardization, reducing operator dependence, increasing reproducibility and enhancing laboratory productivity. Commercially, IKONISYS targets medical laboratories, hospitals and pathology networks in Europe and the United States, supported by an international footprint spanning Paris, Milan, Florence and New Haven. The company emphasizes its transatlantic presence and relies on distribution partnerships, industrial alliances and group synergies to expand market penetration. Notable facts include regulatory validation such as FDA clearances for certain applications, CE-marked products in Europe, and ongoing development of next-generation microscopes and AI-enabled applications intended to further automate cancer diagnostics.